PFBT
SYRE icon

Parkside Financial Bank & Trust’s Spyre Therapeutics SYRE Stock Holding History

Parkside Financial Bank & Trust’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.77K Hold
35
– – ﹤0.01% 2159
2025
Q4 		$1.15K Hold
35
– – ﹤0.01% 2299
2025
Q3 		$587 Hold
35
– – ﹤0.01% 2497
2025
Q2 		$524 Buy
+35
New +$518 ﹤0.01% 2522

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Parkside Financial Bank & Trust's SYRE Position: Q1 2026 in Review

Parkside Financial Bank & Trust held its Spyre Therapeutics (SYRE) position steady in Q1 2026 at 35 shares worth $1.77K. The position accounts for ﹤0.01% of the portfolio, ranked #2159.

Parkside Financial Bank & Trust first reported a position in SYRE in Q2 2025 and has held it in 4 quarters since. 198 funds tracked by Wall St. Rank hold SYRE as of Q1 2026.

  • Parkside Financial Bank & Trust held 35 shares of Spyre Therapeutics worth $1.77K as of Q1 2026.
  • Parkside Financial Bank & Trust left its Spyre Therapeutics share count unchanged in Q1 2026.
  • Spyre Therapeutics made up ﹤0.01% of Parkside Financial Bank & Trust's portfolio in Q1 2026, its #2159 holding.
  • Parkside Financial Bank & Trust first reported a position in Spyre Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 198 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2026.

Based on Parkside Financial Bank & Trust's 13F filing for Q1 2026, filed 13 May 2026.